Viral Infections Respiratory Infections Research & Innovation

PCR system detects SARS-CoV-2 pseudovirus

Share

An integrated microfluidic and plasmonic PCR system detected SARS-CoV-2 pseudovirus at concentrations as low as 10 particles/mL, according to an abstract presented at IDWeek 2026.

McGill University researchers in Montreal sought to address diagnostic challenges from low viral loads and delays associated with centralized RT-PCR testing in settings with limited laboratory resources. “There is a need for rapid, point-of-care diagnostics with high sensitivity and accuracy while decreasing processing time,” they wrote.

The researchers combined microfluidic particle sorting with plasmonic PCR and used aptamer-functionalized magnetic beads to capture the SARS-CoV-2 spike protein. They evaluated bead recovery at different flow rates within the sorting device and tested primer sets targeting the viral N gene for specificity using human coronavirus strains 229E and OC43.

Following aptamer-bead enrichment, the system detected pseudovirus across serial dilutions ranging from 10 to 1 million particles/mL with no detection in negative controls. Average cycle threshold values decreased as viral concentration increased, from 33.84 at 10 particles/mL to 19.67 at 1 million particles/mL.

For the sorting device, maximum magnetic bead recovery was 68.47% at a flow rate of 50 μL/min, compared with55.95% at 100 μL/min. The authors attributed the lower recovery at the higher flow rate to probable effects of hydrodynamic drag and reduced bead residence time within the device.

Magnet spacing also affected bead capture. A distance of 6 mm resulted in partial bead capture, while reducing the distance to 3.68 mm improved bead retention and concentration. “These findings show the importance of magnetic field geometry in optimizing capture efficiency within the MPS device,” the authors wrote.

The researchers described their findings as supporting a fast pipeline for SARS-CoV-2 detection. “Moreover, the work supports the development of specific, sensitive and portable platforms for decentralized testing to meet future outbreak response,” they wrote.

Eight authors reported no financial relationships to disclose. The abstract did not list a disclosure for co-author Luis Arturo Flores Asomoza, a doctoral candidate.